Atai life sciences stock. The associated price target is $6.
Atai life sciences stock. 33%) is having a rough go of things lately .
Atai life sciences stock Net Loss for the year was (40. 20% of Atai Life Sciences stock is atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company focused on mental health disorders, has announced its participation in the H. Its product candidates include Atai Life Sciences had revenue of $40. Monitor the latest movements within the ATAI Life Sciences BV real time stock price chart below. 41% Sumant Kulkarni, an analyst from Canaccord Genuity, maintained the Buy rating on ATAI Life Sciences (ATAI – Research Report). On Friday, ATAI Life Sciences N. Read here for a deep dive on ATAI stock. 12 M) of positive Demonstrates atai’s confidence in COMPASS’ Phase 2b data and its potential for patients with treatment-resistant depression Reinforces COMPASS as highly complementary to atai’s diversified approach to innovation in mental health atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of . 15, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. Dashboard Portfolios Watchlist Community Discover Screener Is Atai Life Sciences stock a buy? At a more than $2 billion valuation, atai will have the highest market cap of all pureplay psychedelic companies currently on the market. Learn more about whether Atai Life Sciences N. 44 +0. , a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. The Company's therapeutic lead compound include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression What's going on at Atai Life Sciences (NASDAQ:ATAI)? Read today's ATAI news from trusted media outlets at MarketBeat. The average price target for Atai Life Sciences N. 00. View atai Life Sciences NV ATAI investment & stock information. ATAI Life Sciences (NASDAQ:ATAI) Stock, Insider Trading Activity October 15, 2024 | benzinga. Learn why top analysts are making this stock forecast for Atai Life Sciences at MarketBeat. 27%) As of 04:00 PM Eastern. V - Stock screener for investors and traders, financial visualizations. 02, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health Net loss attributable to ATAI Life Sciences N. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany. View daily, weekly or monthly format back to when Atai Life Sciences N. Global drug policy is changing, and psychedelic therapies are next in line for decriminalization, research, and sale. 5100 1. 00 USD. atai Life Sciences. OUR VISION. Get ATAI Life Sciences BV (ATAI) share price today, stock analysis, stock rating, price valuation, performance, fundamentals, market cap, shareholding, and financial report. is a clinical-stage biopharmaceutical company focused on developing and investing in therapeutics for mental health disorders such as depression, anxiety, and Stock Info; Corporate Governance; SEC Filings; Shareholder Services; atai News and Media Coverage. Check if this forecast comes true in a year, meanwhile watch ATAI Life Sciences N. 5200 1. The low is $6 issued by Maxim Group on ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. See upgrades, downgrades, price targets and more from top Wall Street stock analysts. What percentage of Atai Life Sciences stock is owned by insiders? 31. (ATAI) Stock Price, Quote, latest community messages, chart, news and other stock related information. Atai, and Srinivas Rao. V. The company was founded by Christian Angermayer, Florian Brand Atai Life Sciences (ATAI) stock gains as Maxim Group upgrades the company, arguing that its recent investment in Beckley Psytech boosts catalyst path. P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key See Atai Life Sciences N. Shares of Atai Life Sciences (ATAI 6. 27M. , Ph. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an Interactive Chart for Atai Life Sciences N. share price today is 1. VLS-01 is designed to induce a short psychedelic experience, allowing for a total in-clinic treatment of 2-hours, consistent with an established commercial paradigm in ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. Common Shares (ATAI) pre market trades, share volumes, and more. 13, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment Get a complete stock price history for Atai Life Sciences, starting from its first trading day. stockholders $ (33,135) $ (36,869) Net loss per share attributable to ATAI Life Sciences N. Esta ferramenta de checklist é fornecida apenas para fins ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is Tudo sobre as ações ATAI Life Sciences BV - Stock (Nasdaq) ATAI, cotação em dólar e reais, dividendos (Dividend Yield - DY), resultados, indicadores fundamentalistas, balanços, gráficos e muito mais. Atai Life Sciences stock has a price to book value of 1. Other Robinhood Financial fees may apply, check rbnhd. analyst ratings, historical stock prices, earnings estimates & actuals. Real time Atai Life Sciences (ATAI) stock price quote, stock graph, news & analysis. , a clinical-stage biopharmaceutical company, develops and invests in various therapeutics Get the latest atai Life Sciences NV ATAI detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Sumant Today, the XBI Biotech Index (a stock market index that tracks the performance of companies primarily involved in the biotechnology sector) crossed 100. (ATAI) stock price, news, historical charts, analyst ratings and financial information from WSJ. 94% over the past week. Compare. This subreddit is dedicated to the discussion of atai Life Sciences and their subsidiaries. Strong Buy. The upgrade of atai Life Sciences to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term. ATAI financial and pipeline updates. I stand by my prediction that biotech will be one of the best performing asset classes this year. 85: 52 Week Low ATAI Life Sciences Stock forecast & analyst price target predictions based on 4 analysts offering 12-months price targets for ATAI in the last 3 months. has been promoted to Chief Medical Officer, Glenn Short, Ph. A high-level overview of Atai Life Sciences N. This has been a highly anticipated event, and it seems as though many are looking to get in. succeeds as sole Chief Executive Officer - Kevin Craig, M. 3. Research Atai Life Sciences' (XTRA:9VC) stock price, latest news & stock analysis. Srinivas Rao, M. View today's ATAI Life Sciences BV stock price and latest ATAI news and analysis. ATAI Life Sciences General Information Description ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. 00K in the quarter ending September 30, 2024, a decrease of -54. The chart below shows how a company's ratings by analysts have changed over time. Find the latest Atai Life Sciences N. atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, with offices in New York, San Diego and Get a complete stock price history for Atai Life Sciences, starting from its first trading day. Volume Jan 13, 2025 1. 00 USD and a min estimate of 5. 81, compared to an industry average of 6. 00K, down -0. (ATAI) with real-time updates, full price history, technical analysis and more. The latest closing stock price for Atai Life Sciences as of January 10, 2025 is 1. Atai Life Sciences N. ATAI's current price target is $9. The latest ATAI Life Sciences stock prices, stock quotes, news, and ATAI history to help you invest and trade smarter. (Ad) Free ATAI Stock Alerts. stock information by Barron's. 02, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health Stock Info; Corporate Governance; SEC Filings; Shareholder Services; Pioneering the development of highly effective mental health treatments that address the unmet needs of patients. has a VGM Score of F (this is a weighted average of the individual Style Scores which allow you to focus on the stocks that best fit your personal trading ATAI Life Sciences BV stock price live, this page displays NASDAQ ATAI stock exchange data. The current market capitalization of ATAI is 251. co/fees for details. is $9. October 29, 2020 Programs 8:22 pm. ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. News Oct 2, 2024. It is down -5. Read on to find out how grades on certain investment factors and determine whether it meets your investment needs. It engages in the treatment of mental health disorders. stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. Index Last % Change; S&P 500: 5,998 ATAI Life Sciences NV has a consensus price target of $11 based on the ratings of 9 analysts. 22 M) with profit before overhead, payroll, taxes, and interest of 233 K. Alright, so it looks like the time has come, and ATAI is set to become public. The Company A high-level overview of Atai Life Sciences N. 43% change over the last 24 hours and -14. A) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments Shares of Atai Life Sciences (ATAI 6. View the ATAI premarket stock price ahead of the market session or assess the after hours quote. promoted to Chief Scientific Officer When is Atai Life Sciences' next earnings announcement? View the latest ATAI earnings date, analysts forecasts, earnings history, and conference call transcripts. Wainwright 5th Annual Neuro Perspectives Conference NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical A community of stock market investors in the legal psychedelics sector. This is based on 4 Wall Streets Analysts 12-month price targets, Atai Life Sciences N. ATAI: 1. 3 months ago - IntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AG - GlobeNewsWire 4 months ago - atai Life Sciences to Participate in the H. ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to You can buy and sell ATAI Life Sciences (ATAI) and other stocks, ETFs, and their options commission-free on Robinhood with real-time quotes, market data, and relevant news. The stock has a atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit NEW YORK and BERLIN, Oct. is based in BERLIN. Using the first lens NEW YORK and BERLIN, Aug. 13, 2024 1 Comment ATAI Life Sciences GAAP EPS of -$0. Is it a good time to buy ATAI Life Sciences stock? Review technicals and fundamentals to help you determine if now's a good time for you to invest. 02%. 19 across pharmaceutical stocks, according to CSIMarket. com atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit DemeRx IB, Inc. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire 4 months ago - Psychedelic Stock Deep Dive: Atai Life Sciences - Seeking Alpha atai Life Sciences. (US:ATAI) has 90 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Stay ahead with Nasdaq. or its management. Please note that any opinions, estimates or forecasts regarding ATAI Life Sciences N. Price Target . Stock analysis for ATAI Life Sciences NV (9VC:Xetra) including stock price, stock chart, company news, key statistics, fundamentals and company profile. The Elements Impacting Atai’s Market Dynamics Atai Life Sciences reports its Q3 atai Life Sciences. 06 M in cash with (84. 80 USD with a max estimate of 11. 83%) More news for this symbol Business Summary atai Life of mental ATAI Life Sciences (ATAI) Company Description: ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. (ATAI) stock analysis from Seeking Alpha’s top analysts: exclusive research and insights from bulls and bears. 68M. (DemeRx), an atai Life Sciences (atai) platform company focused on developing ibogaine for the treatment of opioid use disorder (OUD), today announced that the first subjects have been dosed in a Phase 1/2a clinical trial of ibogaine HCl (DMX-1002). Share your opinion and gain insight from other stock traders and investors. 13, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, with offices in New York, San Diego and Berlin. The associated price target remains the same with $11. La compañía planea iniciar el estudio de Fase 2 de View ATAI Life Sciences N. 00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy Historical daily share price chart and data for Atai Life Sciences since 2008 adjusted for splits and dividends. A list of analyst ratings for Atai Life Sciences (ATAI) stock. ATAI LIFE SCIENCES. P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, with offices in New York, San Diego and Berlin. Founded in 1993, The Motley Fool is a financial services company dedicated to making the (RTTNews) - Biopharmaceutical company atai Life Sciences N. About atai Life Sciences atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders and was founded as a response to the significant unmet need About atai Life Sciences atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders and was founded as a response to the significant unmet need Atai Life Sciences stock has a price to book value of 1. Price graph; Historical data; Technical analysis; Use our graph to track the performance of ATAI stock over atai Life Sciences B. 33%) is having a rough go of things lately The Atai Life Sciences N. stock news by MarketWatch. All Analysts Top Analysts Total Analysts . 41% ATAI Life Sciences N. , has become the sole Chief Executive Officer, while Kevin Craig, M. This might drive the stock higher in the near term. On average, 3 Wall Street analysts forecast ATAI's earnings for 2025 to be -$95,647,366, with the lowest ATAI earnings forecast at -$115,783,653, and the highest ATAI earnings forecast at -$72,155,030. VLS-01 is designed to induce a short psychedelic experience, allowing for a total in-clinic treatment of 2-hours, consistent with an established commercial paradigm in NEW YORK and BERLIN, Jan. A good occasion to re-post my views on atai Life Sciences. This brings the company's revenue in the last twelve months to $331. This is shroomstocks though and we are talking about ATAI which is down 80 atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a ELE-101 is a patent-protected, synthetic formulation of See the latest ATAI Life Sciences NV stock price (ATAI:XNAS), related news, valuation, dividends and more to help you make your investing decisions. ATAI stock quote prices, financial information, real-time forecasts, and company news from CNN. Common Shares (ATAI) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. 89 on June 21, 2021. These institutions hold a total of 13,518,374 shares. stock was issued. Read more here. Learn more on insiders at ATAI. Find everything from its Valuation, Future Growth, Past Performance and more. When analyzing and comparing psychedelic stocks, I study companies through two lenses: the scientific work being completed; and the company’s financials. Stock analysis for ATAI Life Sciences NV (ATAI:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. . 36, revenue of $0. 42, with a volume of 1. 10, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment atai Life Sciences (NASDAQ: ATAI) informó los resultados financieros del tercer trimestre de 2024 y actualizaciones de su pipeline. Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on ATAI Life Sciences (ATAI – Research Report). Interactive stock price chart for Atai Life Sciences N. View ATAI Life Sciences's price performance, share price volatility, historical data and technicals. O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments Stocks. D. A) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments Stocks. Morningstar brands and products See the latest ATAI Life Sciences NV stock price (ATAI:XNAS), related news, valuation, dividends and more to help you make your investing decisions. (ATAI), analyze all the data with a huge range of indicators. Make informed Stock prices may also move more quickly in this environment Why Atai Life Sciences Stock Stormed Higher This Week Motley Fool - Fri Mar 31, 2023 The biotech's strong financial position may be attracting bargain buyers right now. Share. View real-time stock prices and stock quotes for a full financial overview. atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental On Wednesday, atai Life Sciences N. NEW: Price Reaction to Earnings Reports View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Add. Research Atai Life Sciences' (Nasdaq:ATAI) stock price, latest news & stock analysis. (ATAI) stock quote, history, news and other vital information to help you with your stock trading and investing. Our vision is to heal mental health disorders so that everyone everywhere can live a more fulfilled life. has joined as Atai Life Sciences N. Short interest data is updated every two weeks. España India Italia 대한민국 日本 My Account Benzinga Edge Benzinga Research Benzinga Pro Login r/AtaiLifeScience: Official atai Life Sciences subreddit. The company was founded by Christian Angermayer, Florian Brand At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. (ATAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). News Today's news US Politics World Tech Reviews and deals Audio Computing Atai Life Sciences Nv 's earnings in 2025 is -$128,603,000. Get the latest atai Life Sciences NV ATAI detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. 58 percent. 33% in the last 24 hours and up +4. 10, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment When is Atai Life Sciences' next earnings announcement? View the latest ATAI earnings date, analysts forecasts, earnings history, and conference call transcripts. NEW YORK and BERLIN, Jan. Get the latest ATAI - ATAI LIFE SCIENCES NV quote information including top holdings and analyst ratings. 50. For those who haven't had a chance to get Find the latest Atai Life Sciences N. Our vision is to heal mental health disorders so that View the latest ATAI Life Sciences N. 90% year-over-year. Figure out where to buy Atai Life Sciences Nv stock: You need to pick an online brokerage, but don't worry - we've tried dozens of stock brokerages and apps to help you decide where to buy Atai Life Sciences Nv stock. stockholders — basic and diluted $ (0. 3750 1. Company Summary x atai Life Sciences (ATAI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. Should You Buy or Sell Atai Life Sciences Stock? Get The Latest ATAI Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat. stock quotes reflect trades reported According to analysts, ATAI price target is 7. 57%. View now. atai Life Sciences B. Share your ideas and get valuable insights from the Find the latest Atai Life Sciences N. 's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of ATAI Life Sciences N. stockholders — basic and diluted: 155,792,490: 153,529,268 NEW YORK and BERLIN, Jan. Each View the latest ATAI Life Sciences N. 21) $ (0. ATAI Life Sciences N. Safer Psychedelic Drugs May Be Coming. (ATAI) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Get a real-time Atai Life Sciences N. 24) Weighted average common shares outstanding attributable to ATAI Life Sciences N. is followed by the analysts listed. (ATAI) stock price quote with breaking news, financials, statistics, charts and more. View real-time ATAI stock price and news, along with industry-best analysis. (ATAI) stock. (NASDAQ:ATAI), a biotechnology company focused on mental health, received continued support from analysts following the release of its Phase 1 clinical study Discover real-time ATAI Life Sciences N. Wainwright 26th Annual Global Investment Conference Sep 04 2024; atai Life Sciences Reports Second Quarter 2024 Get ATAI Life Sciences NV (ATAI. is a good stock to buy or sell based on recent news as well as its key financial metrics. : ATAI Life Sciences currently holds about 304. promoted to Chief Medical Officer - Glenn Short, Ph. In the year 2023, Atai Life Sciences had annual ATAI Life Sciences Stock (NASDAQ: ATAI) stock price, news, charts, stock research, profile. 41% over the past month. Get the latest ATAI Life Sciences NV (ATAI) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. A) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments atai Life Sciences N. In addition, atai Life Sciences N. atai Life Sciences (NASDAQ: ATAI) has announced significant leadership changes to advance its pipeline of mental health therapeutics. 1900 (-0. Includes open, high, low, close and volume. atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates Nov 13 2024; atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit Oct 15 2024; atai Life Sciences to Participate in the H. What is Insider Activity? Insider trading activity involves company insiders, such as executives, directors, and employees, engaging Atai Life Sciences N V stock is traded at $1. Overview: Atai Life Sciences N. ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. Upside +890. Stock News Furthermore, ATAI Life Sciences’ financial health appears robust, with a cash position reported at the end of the second quarter of 2024 that is expected to sustain company operations well into Shares of Atai Life Sciences (NASDAQ:ATAI) rallied 18% in afternoon trading Thursday after the company announced a $50M investment in psychedelic drug developer Beckley Psytech, which has two The latest atai Life Sciences stock prices, stock quotes, news, and history to help you invest and trade smarter. O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments The upgrade of atai Life Sciences to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term. Summary of share price highs, lows and changes for Atai Life Sciences; Historical stock prices; Current Share Price: US$1. The Company's therapeutic lead compound include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression Short interest for ATAI Life Sciences gives investors a sense of the degree to which investors are betting on the decline of ATAI Life Sciences's stock. Stocks: Real-time U. Track ATAI Life Sciences N. Stock Info; Corporate Governance; SEC Filings; Shareholder Services; Psilocybin. $10. in New York, NY from September 9-11, 2024. C. 27M Get the latest updates on ATAI Life Sciences N. I give my honest opinions on ATAI’s progress ATAI - ATAI Life Sciences N. , Florian Brand, Life Sciences N. With that though, one could easily make both a bullish and bearish argument as to owning the stock. Ratings History. The Company engages in developing various treatments that focuses on various mental health disorders. Get ATAI Life Sciences NV (ATAI. La FDA aprobó el IND para VLS-01 (película bucal de DMT) para la depresión resistente al tratamiento, con el inicio del estudio de Fase 2 esperado alrededor de finales de 2024. (ATAI) stock discussion in Yahoo Finance's forum. 77: 52 Week High: US$2. Index Last % Change; S&P 500: 5,918 Despite lagging behind on clinical trial timelines, Atai Life Sciences still has a deep development portfolio. ATAI updated stock price target summary. Atai Life Sciences psychedelic drug for depression demonstrates safety in phase 1 SA News Tue, Aug. Its product candidates include COMP360, a proprietary psilocybin which is Atai Life Sciences psychedelic drug for depression demonstrates safety in phase 1 SA News Tue, Aug. S. (ATAI) currently has an average brokerage recommendation (ABR) of 1. ’s stock movement is significantly influenced by recent breakthroughs in mental health research and innovative drug development, leading investors to react positively. The high is $18 issued by Loop Capital on November 1, 2022. stock price chart and keep track of the atai Life Sciences N. (ATAI) announced Friday key leadership appointments to advance its goal of delivering novel mental health therapeutics. Srinivas Rao Discover historical prices for ATAI stock on Yahoo Finance. Consensus Rating . The associated price target is $6. Create real-time notifications to follow any changes in the live stock price. Latest Atai Life Sciences N. Skip to main content We use cookies to understand how you use our site and to With its shares down by 60% in the last 12 months and a recent layoff affecting 30% of its workforce, it's fair to say that Atai Life Sciences (ATAI-5. 27M NEW YORK and BERLIN, Nov. Enjoy reading! ATAI Life Sciences: Insider buying and selling updated today. atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, with offices in New York, San Diego and Berlin. Morningstar brands and products Complete ATAI Life Sciences N. The list of insiders at Atai Life Sciences includes Anne Nagengast Johnson, Apeiron Investment Group Ltd. to Chief Scientific Officer, and Gerd Kochendoerfer, Ph. Earnings. MindMed (Nasdaq: MNMD), atai Life Sciences (Nasdaq: ATAI), and Compass Pathways (Nasdaq: CMPS) are three of the largest and most significant psychedelic companies. Wainwright 26th Annual Global Investment Conference in New York, NY from September 9-11, 2024. Open your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've selected. Atai Life Sciences Analyst Ratings. I hope all of you enjoy the video. Skip to content Bloomberg the Company atai Life Sciences to Participate in the H. 7M with an average volume in the last three months of 1. First participant dosed in Phase 1b trial of VLS-01 with data expected in 2H’24; Phase 2 study in TRD patients anticipated to initiate around YE’24 ATAI Life Sciences had very high historical volatility over the last 90 days: ATAI Life Sciences may become a speculative penny stock: The company reported the previous year's revenue of 314 K. Technical analysis. The Company's therapeutic lead compound include PCN-101, a Find the latest Atai Life Sciences N. 11 (+8. The all-time high Atai Life Sciences stock closing price was 19. ’s stocks have been trading up by 10. The trial has commenced enrollment and dosing of recreational drug users and healthy [] NEW YORK and BERLIN, Jan. 62, reflecting a -7. View ATAI Life Sciences N. ATAI News. 78%), a clinical-stage biopharmaceutical company that is developing therapies from psychedelics to treat mental health conditions, saw its shares rise 12. Atai Life Sciences (ATAI) Earnings Date, Estimates & Call Transcripts $1. ATAI | Complete ATAI Life Sciences N. Explore Our Brands WSJ Barron's MarketWatch IBD ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. This could indicate that the stock is undervalued. atai Life Sciences - Srinivas Rao M. is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. pjzmzkktacmzkiqfjbztwpvotvjjhzzvmjiaabizutnhoak